BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Genetown

  F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress

  F-star Therapeutics, Inc. today announced new clinical data from its potentially best-in-class clinical asset FS222, a CD137/PD-L1 targeting tetravalent bispecific antibody.

  December 6, 2022

   · 

  7 min read
• Drug Development

  BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

  BioVie Inc. today announced encouraging data suggesting that NE3107 has an impact on improving patients’ DNA methylation profiles, potentially impacting biomakers of aging-related disease states.

  December 6, 2022

   · 

  11 min read
• Opthea to Present at the FLORetina 2022 Congress

  Opthea Limited announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022.

  December 6, 2022

   · 

  2 min read
• Biotech Beach

  Healis Therapeutics selected to present at 2023 Biotech Showcase in San Francisco

  Healis Therapeutics is pleased to announce that it has been competitively selected to present at the Biotech Showcase taking place January 9-11, 2023 in San Francisco.

  December 6, 2022

   · 

  1 min read
• Drug Development

  Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease

  Pivotal Phase 3 Trial Completed Enrollment Ahead of Schedule Enabling Topline Data Readout and NDA Filing in 2024.

  December 6, 2022

   · 

  9 min read
• Policy

  MTTI Receives Chinese Patent for EVATHERA Technology

  Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform.

  December 6, 2022

   · 

  2 min read
• BioMidwest

  SimBioSys® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022

  SimBioSys ® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022.

  December 6, 2022

   · 

  3 min read
• BioForest

  NanoString Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform

  NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the first commercial shipment of the CosMx™ Spatial Molecular Imager and the AtoMx™ Spatial Informatics Platform.

  December 6, 2022

   · 

  4 min read
• CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient

  China Medical System Holdings Limited (CMS, 867.HK) acquired another blockbuster innovative product in dermatology filed.

  December 6, 2022

   · 

  7 min read
• Business

  Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

  Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

  December 6, 2022

   · 

  10 min read